Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
Dasatinib and nilotinib exhibit similar efficacy in the CML-CP treatment. Individualized patient management should consider patient comorbidities and safety profiles.
Authors
- Ozlem Candan (ORCID: https://orcid.org/0000-0001-8136-3994)
- Işık Atagündüz (ORCID: https://orcid.org/0000-0002-7876-6896)
- Tayfur Toptaş (ORCID: https://orcid.org/0000-0002-2690-8581)
- Meral Uluköylü Mengüç (ORCID: https://orcid.org/0000-0002-4303-9488)
- Fatma Arıkan
- Tülin Tuğlular
- Asu Fergün Yılmaz (ORCID: https://orcid.org/0000-0001-5118-6894)
- Ahmet Mert Yanık (ORCID: https://orcid.org/0000-0002-1908-0149)
- Derya Demirtaş (ORCID: https://orcid.org/0000-0001-9449-8759)
- Secil Salim
Institutions
- Marmara University (TR)
Publication Details
- Journal
- Hematology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1080/16078454.2025.2478344
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31